Diabetic nephropathy: update on pillars of therapy slowing progression
SC Naaman, GL Bakris - Diabetes Care, 2023 - Am Diabetes Assoc
Management of diabetic kidney disease (DKD) has evolved in parallel with our growing
understanding of the multiple interrelated pathophysiological mechanisms that involve …
understanding of the multiple interrelated pathophysiological mechanisms that involve …
A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American …
CE Ndumele, IJ Neeland, KR Tuttle, SL Chow… - Circulation, 2023 - Am Heart Assoc
A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …
Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis
Background: In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D),
finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces cardiovascular …
finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces cardiovascular …
Common metabolic features of hypertension and type 2 diabetes
I Usui - Hypertension Research, 2023 - nature.com
Hypertension and type 2 diabetes frequently coexist, suggesting that the two diseases have
common pathophysiological bases. This review describes the pathophysiological …
common pathophysiological bases. This review describes the pathophysiological …
[HTML][HTML] Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from Diabetes Technology Society
AM Yeung, J Huang, A Pandey, IA Hashim… - Progress in …, 2023 - Elsevier
Abstract Diabetes Technology Society assembled a panel of clinician experts in diabetes,
biomarker screening, and heart failure to review the current evidence on biomarker …
biomarker screening, and heart failure to review the current evidence on biomarker …
Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes
BF Palmer - Diabetes, Obesity and Metabolism, 2023 - Wiley Online Library
For the purpose of predicting clinical outcomes in patients with diabetes and chronic kidney
disease, change in albuminuria is a good candidate to be a surrogate marker for future …
disease, change in albuminuria is a good candidate to be a surrogate marker for future …
Starch-ascorbyl palmitate inclusion complex, a type 5 resistant starch, reduced in vitro digestibility and improved in vivo glycemic response in mice
The prevalence of type 2 diabetes (T2D) has become a major public health concern
worldwide. Slowly digested or indigestible carbohydrates such as resistant starch (RS) are …
worldwide. Slowly digested or indigestible carbohydrates such as resistant starch (RS) are …
Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis
Background Diabetes is a complicated, chronic condition that requires ongoing medical
attention as well as multiple risk-reduction measures beyond glucose control. The …
attention as well as multiple risk-reduction measures beyond glucose control. The …
Urinary metabolites associate with the presence of diabetic kidney disease in type 2 diabetes and mediate the effect of inflammation on kidney complication
C Shi, Y Wan, A He, X Wu, X Shen, X Zhu, J Yang… - Acta Diabetologica, 2023 - Springer
Aims Diabetic kidney disease (DKD) is the one of the leading causes of end-stage kidney
disease. Unraveling novel biomarker signatures capable to identify patients with DKD is …
disease. Unraveling novel biomarker signatures capable to identify patients with DKD is …
Renin–Angiotensin–Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease
DP Murphy, J Wolfson, S Reule… - Journal of the …, 2023 - journals.lww.com
Background Optimal use of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin
II receptor blockers (ARBs) after AKI is uncertain. Methods Using data derived from …
II receptor blockers (ARBs) after AKI is uncertain. Methods Using data derived from …